Warp Sciences secures $215 million funding

Red finger interacts with glowing blue sphere near circuit board — Brecht Corbeel / Unsplash

Warp Sciences has successfully completed a funding round, raising 215 million USD. The investment was led by Lightspeed, with participation from IVP, Premji Invest, Mayfield, Lux Capital, and Menlo Ventures. The company is reportedly valued at 865 million USD.

Founded by Kevin Weil, former Chief Product Officer and head of the scientific team at OpenAI, Warp Sciences aims to integrate artificial intelligence and robotics into drug development laboratories. The company's primary focus will be on optimizing lead compound synthesis, which involves creating different variants of promising molecules and experimentally comparing their properties to help researchers select the most suitable drug candidates for further development.

Warp Sciences plans to establish a chemistry contract research organization in the United States to provide molecular synthesis and testing services for drug development teams. Clients will retain control over their drug projects and decide which molecules to study, as Warp does not intend to develop its own drug pipeline.

To train robots for laboratory tasks, chemical researchers will use camera-equipped gloves to demonstrate and record experimental procedures. The company aims to gradually automate these tasks, allowing laboratories to operate continuously. Data generated from each round of experiments will be used to refine AI models and subsequent experimental designs, forming a cycle of design, execution, analysis, and redesign. The level of automation and actual efficiency will be further developed and verified by the company.

This startup targets the U.S. biotech industry's reliance on overseas research services. The process of batch synthesizing thousands of molecular variants is time-consuming and labor-intensive, traditionally handled by contract research organizations in locations like China. Warp aims to provide alternative services in the United States, reducing geopolitical risks in supply chains and addressing pharmaceutical companies' concerns about intellectual property protection.